Abstract
Ibrutinib works, but does using it set patients up for potential relapse by causing increased genomic instability? This question is addressed in this issue of Blood by Morande et al, who provide convincing evidence that resolves a key safety issue surrounding the use of this drug, giving new insight into its mechanism of action.
Cite
CITATION STYLE
APA
Slupsky, J. R. (2019, May 9). Ibrutinib is safer than we think. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2019-03-901009
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free